Search Dental Tribune

Swedish health care company BioGaia completes investment in MetaboGen

Swedish companies BioGaia and MetaboGen have strengthened their strategic partnership with the final investment of SEK4 million. (Photograph: Pressmaster/Shutterstock)

Fri. 2. December 2016

save

STOCKHOLM, Sweden: Oral health company BioGaia has announced the completion of a strategic two-year equity investment of SEK12 million (€1.2 million) in MetaboGen, a Gothenburg-based research company specialising in metagenomics. With the final payment of SEK4 million (€409.436)—the first two tranches were made in December 2014 and 2015, respectively—BioGaia now holds a 36 per cent share in MetaboGen.

In December 2014, the two companies first announced their strategic partnership. Consequently, BioGaia CEO Peter Rothschild was appointed MetaboGen chairman of the board in 2015.

MetaboGen was jointly founded by Prof. Fredrik Bäckhed from the Department of Molecular and Clinical Medicine at the University of Gothenburg and Prof. Jens B. Nielsen, Head of the Division of Systems and Synthetic Biology at Chalmers University of Technology, together with GU Holding (now GU Ventures) in 2011.

Specialising in metagenomics, the study of the relationship between microbial diversity, genetic variation, and health and disease using gene-sequencing technologies, the research company aims to develop new treatments and products for various metabolic and other microbial-associated diseases by influencing large parts of the microbiota. “Our research coupled with BioGaia’s knowledge and experience in developing and marketing microbial based products is a unique combination that has high likelihood of success,” remarked MetaboGen co-founder Bäckhed on the investment agreement in 2014.

BioGaia’s probiotic products are sold in over 80 countries around the world and include its well-known ProDentis lozenges and the range of ProTectis solutions, containing Lactobacillus reuteri Protectis, BioGaia’s own patented probiotic bacterial strain. According to the company, the natural lactic acid bacterium has been clinically proven to inhibit inflammation and periodontal pathogens.

To post a reply please login or register
advertisement
advertisement